Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial

SAN DIEGO – An experimental tablet from Eli Lilly led to 14.7% weight reduction on the best dose in a 36-week trial, heating up the rising competitors amongst drugmakers to develop an efficient oral weight problems remedy.

The mid-stage outcomes for orforglipron match the estimates of 14-15% weight reduction that Lilly gave in an investor name late final yr. The complete outcomes, printed Friday within the New England Journal of Medication, had been offered right here to a packed convention room on the American Diabetes Affiliation convention.

By the tip of trial, the authors stated, individuals’ weight reduction had not plateaued, suggesting potential for even larger weight reduction over an extended remedy interval.